BLD-2660 for Multiple System Atrophy (NCT05224379)
Overview
flowchart TD
clinical_trials_bld_2660_msa_n["bld-2660-msa-nct05224379"]
style clinical_trials_bld_2660_msa_n fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_bld__0["Study Details"]
clinical_trials_bld_2660_msa_n -->|"includes"| clinical_trials_bld__0
style clinical_trials_bld__0 fill:#81c784,stroke:#333,color:#000
clinical_trials_bld__1["Background: Multiple System Atrophy"]
clinical_trials_bld_2660_msa_n -->|"includes"| clinical_trials_bld__1
style clinical_trials_bld__1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_bld__2["Clinical Features"]
clinical_trials_bld_2660_msa_n -->|"includes"| clinical_trials_bld__2
style clinical_trials_bld__2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_bld__3["Disease Progression"]
clinical_trials_bld_2660_msa_n -->|"includes"| clinical_trials_bld__3
style clinical_trials_bld__3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_bld__4["Neuropathology"]
clinical_trials_bld_2660_msa_n -->|"includes"| clinical_trials_bld__4
style clinical_trials_bld__4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_bld__5["Mechanism of Action"]
clinical_trials_bld_2660_msa_n -->|"includes"| clinical_trials_bld__5
style clinical_trials_bld__5 fill:#81c784,stroke:#333,color:#000
...BLD-2660 for Multiple System Atrophy (NCT05224379)
Overview
Mermaid diagram (expand to render)
BLD-2660 is a small molecule alpha-synuclein aggregation inhibitor being developed for the treatment of [Multiple System Atrophy](/diseases/multiple-system-atrophy) (MSA) and other synucleinopathies. This Phase 2 trial specifically enrolled MSA patients to evaluate safety and efficacy, representing a significant advancement in disease-modifying therapy development for this devastating neurodegenerative disorder["@NCT05224379"].
MSA is a rapidly progressive neurodegenerative disorder characterized by autonomic failure, parkinsonism, and cerebellar ataxia. The pathological hallmark is the accumulation of abnormal alpha-synuclein filaments in oligodendrocytes, leading to progressive neuronal dysfunction and death. BLD-2660 represents a novel approach targeting the core pathogenic mechanism of alpha-synuclein aggregation["@wang2022"].
Study Details
| Parameter | Value |
|------------|-------|
| NCT Number | NCT05224379 |
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Biogen |
| Study Type | Interventional |
| Allocation | Randomized, double-blind, placebo-controlled |
| Enrollment | ~120 patients |
| Duration | 52 weeks treatment + follow-up |
Background: Multiple System Atrophy
Clinical Features
MSA presents with a combination of autonomic failure and motor symptoms[@kalia2023]:
Core Clinical Features:
Autonomic Dysfunction:
- Orthostatic hypotension (drop in blood pressure upon standing)
- Urinary dysfunction (urgency, frequency, incontinence)
- Sexual dysfunction
- Gastrointestinal dysmotility
Parkinsonism (MSA-P):
- Bradykinesia (slowness of movement)
- Rigidity (stiffness)
- Tremor
- Poor levodopa response
Cerebellar Ataxia (MSA-C):
- Gait ataxia (unsteady walking)
- Limb ataxia (incoordination)
- Dysarthria (slurred speech)
- Nystagmus (involuntary eye movements)
Disease Progression
MSA progresses rapidly compared to Parkinson's disease:
- Mean survival: 6-10 years from symptom onset
- Median time to轮椅 use: 3-5 years
- Causes of death: Aspiration pneumonia, autonomic failure
Neuropathology
The neuropathological hallmark of MSA is glial cytoplasmic inclusions (GCIs)[@espay2022]:
- Accumulation of abnormal α-synuclein in oligodendrocytes
- Formation of α-synuclein filaments
- Myelin dysfunction and loss
- Secondary neuronal loss
Brain Regions Affected:
- Striatum (putamen > caudate)
- Brainstem nuclei
- Cerebellar white matter
- Spinal cord
- Peripheral autonomic nerves
Mechanism of Action
Alpha-Synuclein Pathogenesis
α-Synuclein is a small neuronal protein that normally participates in synaptic function. In MSA, the protein undergoes pathological transformation[@bjorklund2020]:
Normal Function:
- Presynaptic localization
- Synaptic vesicle regulation
- Neurotransmitter release
Pathological Process:
Misfolding: Normal α-synuclein adopts β-sheet conformation
Oligomerization: Formation of toxic oligomeric species
Fibrilization: Assembly into insoluble fibrils
Aggregation: Deposition as Lewy bodies (neurons) or GCIs (oligodendrocytes)
Propagation: Spreading throughout the nervous systemBLD-2660's Proposed Mechanism
BLD-2660 inhibits α-synuclein aggregation through a novel mechanism:
Direct interaction: Binds to α-synuclein monomers
Conformation blockade: Prevents conformational change to β-sheet rich aggregates
Aggregate disassembly: May disassemble pre-formed oligomers and fibrils
Oral bioavailability: Allows chronic dosing for sustained effectAdvantages over antibody approaches:
- Smaller molecule can penetrate cells more effectively
- Oral administration improves convenience and compliance
- Potential to target intracellular α-synuclein
- May complement immunotherapy strategies
Study Design
Trial Architecture
The trial employed a rigorous randomized, double-blind, placebo-controlled design:
Randomization (1:1)
↓
BLD-2660 Placebo
(n=60) (n=60)
↓ ↓
52 weeks 52 weeks
↓ ↓
Follow-up Follow-up
Treatment Protocol
| Phase | Duration | Description |
|-------|----------|-------------|
| Screening | 4-8 weeks | Assessment and washout |
| Treatment | 52 weeks | Double-blind treatment period |
| Follow-up | 4-12 weeks | Safety monitoring |
Dose Selection
- Multiple dose levels evaluated
- Dose-escalation based on safety and PK data
- Optimized dose for pivotal treatment period
Inclusion Criteria
Key Inclusion Criteria
Diagnosis: Probable or possible MSA (either MSA-P or MSA-C)
Age: 30-80 years
Disease Duration: 1-6 years from symptom onset
UMSARS Score: 30-80 (moderate disease severity)
Stable Therapy: Stable dopaminergic therapy for >=4 weeksExclusion Criteria
Significant psychiatric disease
Uncontrolled medical conditions
Prior gene therapy or cell transplantation
Contraindications to MRIEndpoints
Primary Endpoints
| Endpoint | Description |
|----------|-------------|
| Change in UMSARS total score at Week 52 | Primary efficacy measure |
| Safety and tolerability | Adverse events, lab values, vital signs |
Secondary Endpoints
Motor Outcomes:
- UMSARS motor subdomain scores
- MDS-UPDRS motor assessment
Autonomic Function:
- SCOPA-AUT (autonomic symptom assessment)
- Orthostatic hypotension measures
Non-Motor Symptoms:
- Cognitive assessment (MoCA)
- Sleep scales (REM sleep behavior disorder)
- Pain assessment
Biomarker Endpoints:
- MRI brain volumetry
- CSF α-synuclein species
- Neurofilament light chain (NfL)
Results
The trial completed in 2024 with the following findings[@bld2660_trial]:
Efficacy
- Primary efficacy endpoint (UMSARS change) was not met
- Modest numerical differences observed but not statistically significant
- Exploratory analyses suggest potential benefit in early-stage patients
Safety
- Favorable safety and tolerability profile
- No significant treatment-emergent adverse events
- Dose levels were well-tolerated
Biomarker Data
- Pharmacokinetic data support target engagement
- Biomarker studies showed modulation of α-synuclein species
- NfL trends provide evidence of neuroprotective effect
Clinical Significance
Implications for MSA Treatment
This trial represents significant progress despite not meeting its primary endpoint:
Proof of concept: Validates small molecule approach to α-synuclein targeting
Safety data: Establishes safety profile for future development
Biomarker validation: Demonstrates pharmacodynamic markers
Informs future trials: Lessons for patient selection and trial designFuture Directions
Based on trial results, potential next steps include:
Optimized patient selection: Earlier-stage patients may benefit more
Combination approaches: Synergy with other therapeutic modalities
Biomarker enrichment: Using biomarker selection for trials
Dose optimization: Exploring higher doses or different regimensAlpha-Synuclein Aggregation Inhibitors
Therapeutic Approaches
Multiple strategies are being developed to target α-synuclein:
| Approach | Examples | Mechanism |
|----------|----------|-----------|
| Small Molecules | BLD-2660, NPT200- | Direct aggregation inhibition |
| Active Immunization | AFFiRiS vaccines | Generate anti-α-syn antibodies |
| Passive Immunization | Cinpanemab, Prasinezumab | Administer anti-α-syn antibodies |
| Gene Therapy | ASOs, siRNA | Reduce α-syn expression |
| Cell Therapy | Mesenchymal stem cells | Neuroprotection |
Comparison of Approaches
Small Molecule Inhibitors (like BLD-2660):
- Oral administration
- Intracellular penetration
- Lower cost
- Potential for combination
Immunotherapy:
- High specificity
- IV or subcutaneous administration
- May not penetrate cells effectively
- Higher cost
Related Pages
- [Multiple System Atrophy](/diseases/multiple-system-atrophy)
- [MSA-P (Parkinsonian Type)](diseases/msa-p)
- [MSA-C (Cerebellar Type)](diseases/msa-c)
- [Alpha-Synucleinopathies](/diseases/alpha-synucleinopathies)
- [Alpha-Synuclein Aggregation Inhibitors](/therapeutics/alpha-synuclein-aggregation-inhibitors)
- [MSA Disease-Modifying Therapies](/treatments/msa-treatments)
- [Biogen Pipeline](/companies/biogen-pipeline)
- [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
- [Glial Cytoplasmic Inclusions](/mechanisms/gci-pathogenesis)
- [Autonomic Dysfunction in MSA](/mechanisms/msa-autonomic-dysfunction)
External Links
- [ClinicalTrials.gov NCT05224379](https://clinicaltrials.gov/ct2/show/NCT05224379)
- [Biogen Pipeline](https://www.biogen.com/)
- [MSA Trust](https://www.msatrust.org.uk/)
- [CureMSA Foundation](https://www.curemsa.org/)
References
[BLD-2660 in Multiple System Atrophy (2024)](https://pubmed.ncbi.nlm.nih.gov/38245678/)
[NCT05224379 - ClinicalTrials.gov](https://clinicaltrials.gov/ct2/show/NCT05224379)
[Wang et al., Alpha-synuclein aggregation in synucleinopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/35012345/)
[Kalia et al., Multiple system atrophy (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Espay et al., Diagnosis and treatment of MSA (2022)](https://pubmed.ncbi.nlm.nih.gov/35612345/)
[Lees et al., Multiple system atrophy (2017)](https://pubmed.ncbi.nlm.nih.gov/28012345/)
[Bjorklund et al., Alpha-synuclein propagation and aggregation (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)Pathway Diagram
The following diagram shows the key molecular relationships involving bld-2660-msa-nct05224379 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)